Both Retatrutide and Ozempic/Wegovy trials met high standards for methodology, though understanding their differences adds context to the efficacy comparisons
5 earnings call its Q3 2025 net profit fell 27% YoY to $3.1 billion, after which its stock fell more than 2%
April 16, 2025: Attorneys In Group Zepbound Lawsuit Argue Over How to Diagnose Gastroparesis Attorneys representing people harmed by Zepbound are trying to find common ground on the terms for a gastroparesis diagnosis
Healthcare Cost and Insurance Coverage The high cost of GLP-1 drugs poses a major limitation, especially in healthcare systems with restricted reimbursement policies
Imitating its action, many beneficial effects are achieved, the most important ones are muscle growth and strength, fat loss, rapid recovery, tissue regeneration, and improved cognition